EDGAR Filing Documents for 0001437749-19-024424

Form 8-K - Current report:

SEC Accession No. 0001437749-19-024424

Filing Date

2019-12-13

Accepted

2019-12-13 16:19:18

Documents

Period of Report

2019-12-11

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	dffn20191212_8k.htm	8-K	37956
2	EXHIBIT 4.1	ex_167361.htm	EX-4.1	111116
3	EXHIBIT 4.2	ex_167362.htm	EX-4.2	116117
4	EXHIBIT 5.1	ex_167363.htm	EX-5.1	12740
5	EXHIBIT 10.1	ex_167364.htm	EX-10.1	225805
6	EXHIBIT 10.2	ex_167365.htm	EX-10.2	60598
7	EXHIBIT 99.1	ex_167366.htm	EX-99.1	14360
8	EXHIBIT 99.2	ex_167368.htm	EX-99.2	14236
9		dechertlogo02.jpg	GRAPHIC	5066
10		hcwainwrightlogo02.jpg	GRAPHIC	12831
11		logo01.jpg	GRAPHIC	4559
	Complete submission text file	0001437749-19-024424.txt		625378

Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902

Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718

Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)